Pegfilgrastim vs. filgrastim for supportive care after autologous stem cell transplantation: Can we decide?

Clinical Transplantation

Volumn 26, Issue 1, 2012, Pages 16-22

  Ziakas, Panayiotis D ^a   Kourbeti, Irene S ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Chalkida General Hospital   (Greece)

Author keywords

Autologous; Filgrastim; Pegfilgrastim; Transplantation

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ABSOLUTE NEUTROPHIL COUNT; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE PAIN; COCHRANE LIBRARY; COST BENEFIT ANALYSIS; DISEASE DURATION; DRUG COST; EMBASE; FEBRILE NEUTROPENIA; HUMAN; LENGTH OF STAY; MEDLINE; NEUTROPHIL COUNT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

ANIMALS; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; PALLIATIVE CARE; RECOMBINANT PROTEINS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84856640618     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2011.01532.x     Document Type: Review

References (38)

1. Haspel RL, Miller KB. Hematopoietic stem cells: source matters. Curr Stem Cell Res Ther 2008: 3: 229.
2. Smith TJ, Klatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006: 24: 5207.
3. Aapro MS, Bohlius J, Cameron DA et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011: 47: 8.
4. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986: 7: 177.
5. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from:.
6. O'Rourke K. Mixed means and medians: a unified approach to deal with disparate outcome summaries. Symposium on Systematic Reviews: Pushing the Boundaries. Oxford, 2002: 49.
7. Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. Br Med J 2003: 32: 557.
8. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. San Diego: Academic Press Inc., 1985.
9. Hedges LV. Fixed effects models. In: Cooper H, Hedges LV eds. The Handbook of Research Synthesis, 2nd edn. New York: Russel Sage Foundation, 1994: 285.
10. Mantel N, Haenzel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959: 22: 719.
11. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997: 127: 820.
12. Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997: 315: 629.
13. Musto P, Scalzulli PR, Terruzzi E et al. Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature. Leuk Res 2007: 31: 1487.
14. Neumeister P, Holub R, Staber PB et al. Pegfilgrastim shows safety and efficacy similar to filgrastim in patients undergoing autologous stem cell transplantation for hematological malignancies. J Support Oncol 2005: 3(Suppl 1): 70.
15. Jagasia MH, Greer J, Kassim A et al. Pegylated filgrastim after high dose chemotherapy and autologous stem cell transplant. Supp Oncol 2005: 3(Suppl 1): 68.
16. Musso M, Porretto F, Crescimanno A et al. Filgrastim (G-CSF) versus pegfilgrastim after autologous peripheral haematopoietic stem cell transplant in patients with haematological malignancies. Bone Marrow Transplant 2005: 35(Suppl 2): S331.
17. Staber PB, Holub R, Linkesch W et al. Fixed-dose single administration of pegfilgrastim vs daily filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2005: 35: 889.
18. Jagasia MH, Greer JP, Morgan DS et al. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Transplant 2005: 35: 1165.
19. Vanstraelen G, Frère P, Ngirabacu MC et al. Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp Hematol 2006: 34: 382.
20. Martino M, Pratico G, Messina G et al. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol 2006: 77: 410.
21. Ballestrero A, Boy D, Gonella R et al. Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. Ann Hematol 2008: 87: 49.
22. Wannesson L, Luthi F, Zucca E et al. Pegfilgrastim accelerates neutrophil engraftment, reduces the number of neutropenic and hospitalization days and the use of antibiotics after autologous peripheral blood stem cell transplant for multiple myeloma and lymphoma. A phase II study and comparison with a filgrastim treated historical cohort. Blood (ASH Annual Meeting Abstracts) 2009: 114: 896 (Abstract 2274).
23. Auger S, Quittet P, Bozonnat MC et al. Febrile neutropenia, mucositis and duration of hospitalization are reduced after pegfilgrastim following autologous peripheral blood stem cell transplantation (PBSCT) for malignant lymphopathies: report of 683 PBSCTs from a single institution. Blood (ASH Annual Meeting Abstracts) 2009: 114: 1324 (Abstract 3410).
24. Castagna L, Bramanti S, Levis A et al. Pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous peripheral blood stem cell support. Ann Oncol 2010: 21: 1482.
25. Samaras P, Blickenstorfer M, Siciliano RD et al. Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. Ann Hematol 2011: 90: 89.
26. Rifkin R, Spitzer G, Orloff G et al. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010: 10: 186.
27. Mathew S, Adel N, Rice RD et al. Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients. Bone Marrow Transplant 2010: 45: 1522.
28. Gerds A, Fox-Geiman M, Dawravoo K et al. Randomized phase III trial of pegfilgrastim versus filgrastim after autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2010: 16: 678.
29. Evans SO, Dignan F, Shaw BE et al. Clinical and economic benefits of using pegfilgrastim post autologous stem cell transplant. Bone Marrow Transplant 2010: 45: 317 (Abstract 1007).
30. Samaras P, Buset EM, Siciliano RD et al. Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation. Oncology 2010: 79: 93.
31. Ferrara F, Izzo T, Criscuolo C et al. Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis. Hematol Oncol 2010: DOI:.
32. Kobbe G, Bruns I, Fenk R et al. Pegfilgrastim for PBSC mobilization and autologous SCT. Bone Marrow Transplant 2009: 43: 669.
33. Bennett CL, George SL, Vose JM et al. Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials. Stem Cells 1995: 13: 414.
34. Klumpp TR, Mangan KF, Goldberg SL et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995: 13: 1323.
35. Gulati S, Bennett C, Toia M et al. Role of granulocyte-macrophage colony stimulating factor (GM-CSF) after autologous bone marrow transplantation for Hodgkin's disease. Anticancer Drugs 1993: 4(Suppl 1): 13.
36. Bennett CL, Stimson TJ, Bhoopalam N et al. A double-blind randomized trial of toxicity, resource use, and cost for filgastrim and sargramostim. Program and abstracts of the ASCO 36th annual meeting; May 20-23, 2000. New Orleans, LA. Abstract 1712.
37. Jansen J, Thompson EM, Hanks S et al. Hematopoietic growth factor after autologous peripheral blood transplantation: comparison of G-CSF and GM-CSF. Bone Marrow Transplant 1999: 23: 1251.
38. Heaney ML, Toy EL, Vekeman F et al. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. Cancer 2009: 115: 4839.